Bisulfite-containing propofol: Is it a cost-effective alternative to Diprivan(TM) for induction of anesthesia?

Xinli Shao, Hong Li, Paul F. White, Kevin W. Klein, Christine Kulstad, Andrew Owens

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Propofol (Diprivan(TM); AstraZeneca, Wilmington, DE) is a commonly used drug for the induction of general anesthesia in the ambulatory setting. With the availability of a new bisulfite-containing generic formulation of propofol, questions have arisen regarding its cost effectiveness and safety compared with Diprivan(TM). Two hundred healthy outpatients were randomly assigned, according to a double-blinded protocol, to receive either Diprivan(TM) or bisulfite-containing propofol 1.5 mg/kg IV as part of a standardized induction sequence. Maintenance of anesthesia consisted of either desflurane (4%-8% end-tidal) or sevoflurane (1%-2% end-tidal) in combination with a remifentanil infusion (0.125 μg · kg-1 · min-1 IV). Patient assessments included pain on injection, induction time, hemodynamic and bispectral electroencephalographic changes during induction, emergence time, and incidence of postoperative nausea and vomiting. The two propofol groups were comparable demographically, and the induction times and bispectral index values during the induction were also similar. However, the bisulfite-containing formulation was associated with less severe pain on injection (5% vs 11%), with fewer patients recalling pain on injection after surgery (38% vs 51%, P < 0.05). None of the patients manifested allergic-type reactions after the induction of anesthesia. The acquisition cost (average wholesale price in US dollars) of a 20-mL ampoule of Diprivan(TM) was $15 compared with $13 for the bisulfite-containing propofol formulation. Therefore, we concluded that the bisulfite-containing formulation of propofol is a cost-effective alternative to Diprivan(TM) for the induction of outpatient anesthesia.

Original languageEnglish (US)
Pages (from-to)871-875
Number of pages5
JournalAnesthesia and analgesia
Issue number4
StatePublished - 2000

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Bisulfite-containing propofol: Is it a cost-effective alternative to Diprivan(TM) for induction of anesthesia?'. Together they form a unique fingerprint.

Cite this